Delayed bystander CD8 T cell activation, early immune pathology and persistent dysregulation characterise severe COVID-19

Laura Bergamaschi,Federica Mescia,Lorinda Turner,Aimee Hanson,Prasanti Kotagiri,Benjamin J. Dunmore,Hélène Ruffieux,Aloka De Sa,Oisín Huhn,Michael D Morgan,Pehuen Pereyra Gerber,Mark R. Wills,Stephen Baker,Fernando J Calero-Nieto,Rainer Doffinger,Gordon Dougan,Anne Elmer,Ian G Goodfellow,Ravindra K. Gupta,Myra Hosmillo,Kelvin Hunter,Nathalie Kingston,Paul J. Lehner,Nicholas J. Matheson,Jeremy K. Nicholson,Anna M. Petrunkina,Sylvia Richardson,Caroline Saunders,James E.D. Thaventhiran,Erik J. M. Toonen,Michael P. Weekes,Berthold Göttgens,Mark Toshner,Christoph Hess,John R. Bradley,Paul A. Lyons,Kenneth G.C. Smith,

DOI: https://doi.org/10.1101/2021.01.11.20248765

2021-01-15

Abstract:Summary In a study of 207 SARS-CoV2-infected individuals with a range of severities followed over 12 weeks from symptom onset, we demonstrate that an early robust bystander CD8 T cell immune response, without systemic inflammation, is characteristic of asymptomatic or mild disease. Those presenting to hospital had delayed bystander responses and systemic inflammation already evident at around symptom onset. Such early evidence of inflammation suggests immunopathology may be inevitable in some individuals, or that preventative intervention might be needed before symptom onset. Viral load does not correlate with the development of this pathological response, but does with its subsequent severity. Immune recovery is complex, with profound persistent cellular abnormalities correlating with a change in the nature of the inflammatory response, where signatures characteristic of increased oxidative phosphorylation and reactive-oxygen species-associated inflammation replace those driven by TNF and IL-6. These late immunometabolic inflammatory changes and unresolved immune defects may have clinical implications.